Skip to main content
      RT @Janetbirdope: Sounds fishy! Krill oil in #osteoarthritis is not a good catch! Fully neg RCT POS0276 @eular_org @Rheu

      Janet Pope Janetbirdope

      3 years 6 months ago
      Sounds fishy! Krill oil in #osteoarthritis is not a good catch! Fully neg RCT POS0276 @eular_org @RheumNow #EULAR2021 https://t.co/OGZbltDyxg
      RT @ejdein1: How many of your postmenopausal RA ♀️ patients are on osteoporotic treatment?
      #EULAR2021 POS0164
      ⭐️

      Eric Dein ejdein1

      3 years 6 months ago
      How many of your postmenopausal RA ♀️ patients are on osteoporotic treatment? #EULAR2021 POS0164 ⭐️28% had prior fragility FX ⭐️50.5% at very high or high risk of fx according to FRAX 10 yr major fx risk Over 1/2 of patients at risk & indicated for treatment! @RheumNow
      RT @Janetbirdope: Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow

      Janet Pope Janetbirdope

      3 years 6 months ago
      Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs (cont'd):
      *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
      🚫strong rec

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 6 months ago
      2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
      RT @jeffsparks: Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence

      Jeffrey Sparks MD MMSc jeffsparks

      3 years 6 months ago
      Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope
      RT @Janetbirdope: Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 3

      Janet Pope Janetbirdope

      3 years 6 months ago
      Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi*⃣Peri

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 6 months ago

      2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

      RT @Janetbirdope: wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has wo

      Janet Pope Janetbirdope

      3 years 6 months ago
      wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has worse outcomes but clusters racially (⬇️ by skin tone) & seems related to SES. But perhaps adding vit D can help immune system & be anti-inflammatory #EULAR2021 @RheumNow POS0100 https://t.co/TEf52bLs0i
      RT @doctorRBC: Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response⭐️HAQ-DI response⭐ï

      Robert B Chao, MD doctorRBC

      3 years 6 months ago

      Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

      RT @doctorRBC: Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
      ⭐️ACR20, 50,70 response

      Robert B Chao, MD doctorRBC

      3 years 6 months ago
      Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow
      RT @doctorRBC: Latest GRAPPA guidelines for treatment of PsA
      Abs#OP0229
      #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8

      Robert B Chao, MD doctorRBC

      3 years 6 months ago
      Latest GRAPPA guidelines for treatment of PsA Abs#OP0229 #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8
      RT @MeralElRamahiMD: What can define +MRI for active spine lesions in axSpA?
      *⃣ BME in >/=4 vertebral corners (VCs

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 6 months ago
      What can define +MRI for active spine lesions in axSpA? *⃣ BME in >/=4 vertebral corners (VCs) *⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion *⃣BME in >/=1 VC if w/ at least 2 VC fat lesions Such cut-offs achieve >/= 95% specificity OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK
      RT @doctorRBC: Lower ILD incidence in PsA than RA in a large Nordic registry
      ⭐️ No significant ⬆️ in ILD in tho

      Robert B Chao, MD doctorRBC

      3 years 6 months ago
      Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
      ×